Kingsley Lawrence D sold $1.2M of IDXX

Kingsley Lawrence D sold 2,203 shares of IDEXX LABORATORIES INC /DE (IDXX) at $532.08 ($1.17M total) on 2026-09-04.

Original reporting
SEC EDGAR · Kingsley Lawrence D
Published Sep 9, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IDXX
Bearish
medium confidence
Mentioned
$IDXX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IDXXBearishLow
01

Why it matters

The director's sale reduces insider ownership, which may be interpreted as a bearish sign, but the amount is relatively small.

02

Market read

Insider sale news is relevant for short-term traders focusing on micro‑cap movements.

03

What to watch

Potential upcoming earnings or corporate actions not disclosed.

Relevance 6/10Novelty 6/10Timing: filing after market close on Sep 9, 2026

Background

Form 4 filings disclose insider transactions; traders monitor director sales for cues.

Company-level read

Ticker impact

$IDXXBearishMedium confidence
Context

Director Kingsley Lawrence D sold 2,203 shares of IDEXX Laboratories for $1.17 M, reducing his stake to 9,568 shares.

Expected impact

Possible modest downside pressure in the next trading session.

Evidence & confidence

Sale size is modest relative to market cap, but director-level insider activity is closely watched by traders.

Market effects

Minimal impact on the broader diagnostics sector.

Limited to U.S. markets where IDEXX trades.

Low global relevance.

Counterpoint

The sale could be a routine liquidity move, not a negative signal.

Key entities

  • IDEXX Laboratories Inc.

    Provider of diagnostic and information technology solutions for animal health.

  • Kingsley Lawrence D

    Director of IDEXX Laboratories.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IDXXHighAI 8/10

IDEXX Laboratories Inc (IDXX) (Q3 2026) Earnings Call Highlights: Raised Outlook

IDEXX Laboratories reported Q3 2026 earnings, raising its full-year organic growth outlook to nearly 10% despite challenges. US clinic visits declined 1.8%, and macro pressures impacted puppy/kitten adoptions. CoVet acquisition is expected to dilute EPS by $0.13 in 2026. Global Rapid Assay revenues grew 1% organically. The company attributed growth to innovations, record instrument placements, and higher-quality visits.